Australian healthcare company Stirling Products Limited (ASX:STI) advises that the Company’s first shipment of bulk botanical product arrived in Canada overnight and is now awaiting Bond clearance. Establishing export arrangements for the export of finished botanical products in bulk with the Ukraine has proven to be a significant exercise. Livingston International, a leading North American provider of global customs and freight services, has been appointed as the Company’s freight and logistics agent. Under their direction and with the support of a number of industry experts, the Company has now successfully established the protocol for all future exports to be seamlessly processed. Following Customs clearance, the bulk imported products will be shipped to Qpharm Inc who has been contracted to complete the Company’s compliance bottling and packaging in readiness for sale in the North American markets. Following receipt of today’s delivery all final compliance and packaging design work will now be completed. The Company will then have sufficient initial inventory to support gross sales of its first four lead products (including ImunoXel) of over US 800,000 in the first few months of the forthcoming network marketing initiative announced last week. For further information see www.stirlingproducts.net or contact: Peter Boonen Managing Director Stirling Products Limited Ph: +61 2 9299 9270 E: [email protected] For all Investor Relations inquiries please contact: James Moses Mandate Corporate Ph: +61 420 991 574 E: [email protected]
STI Price at posting:
1.0¢ Sentiment: ST Buy Disclosure: Held